RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE

Mersana Therapeutics Equity 2024

Mersana Therapeutics Equity

36.9 M USD

Mersana Therapeutics Dividend yield

Ticker

MRSN

ISIN

US59045L1061

WKN

A2DTR7

In 2024, Mersana Therapeutics's equity was 36.9 M USD, a -59.93% increase from the 92.1 M USD equity in the previous year.

Mersana Therapeutics Aktienanalyse

What does Mersana Therapeutics do?

Mersana Therapeutics Inc is a biotechnology company based in Cambridge, Massachusetts, USA. Founded in 2001, the company focuses on developing novel targeted cancer therapies based on the innovative Targeted Payload Apex platform. The company's pipeline includes multiple product candidates in various stages of clinical development, including XMT-1536 and XMT-1592. Mersana Therapeutics Inc collaborates with leading oncologists, scientists, and research institutes to advance its technologies and develop high-quality, safe, and effective therapies for cancer patients. The company's business model is based on utilizing its technology platform and product discovery capabilities to develop novel drugs. It is divided into different business areas targeting different medical applications, including oncology, ophthalmology, immunology, and metabolic diseases. Mersana Therapeutics Inc aims to improve the efficacy, safety, and tolerance of cancer therapies and meet the unmet medical need for targeted cancer treatments. Mersana Therapeutics ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Equity Details

Analyzing Mersana Therapeutics's Equity

Mersana Therapeutics's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding Mersana Therapeutics's equity is essential for assessing its financial health, stability, and value to shareholders.

Year-to-Year Comparison

Evaluating Mersana Therapeutics's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.

Impact on Investments

Mersana Therapeutics's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.

Interpreting Equity Fluctuations

Fluctuations in Mersana Therapeutics’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.

Frequently Asked Questions about Mersana Therapeutics Stock

What is the equity of Mersana Therapeutics this year?

Mersana Therapeutics has equity of 36.9 M USD this year.

What was the equity of Mersana Therapeutics compared to the previous year?

The equity of Mersana Therapeutics has increased/decreased by -59.93% decreased compared to the previous year.

What impact does a high equity have on investors of Mersana Therapeutics?

A high equity is advantageous for investors of Mersana Therapeutics as it is an indicator of the company's financial stability and its ability to manage risks and challenges.

What impact does low equity have on investors of Mersana Therapeutics?

A low equity can be a risk for investors of Mersana Therapeutics, as it can put the company in a weaker financial position and impair its ability to manage risks and challenges.

How does an increase in equity of Mersana Therapeutics affect the company?

An increase in equity of Mersana Therapeutics can strengthen the company's financial position and improve its ability to make investments in the future.

How does a reduction in the equity of Mersana Therapeutics affect the company?

A reduction in equity of Mersana Therapeutics can affect the financial situation of the company and lead to a higher dependence on debt capital.

What are some factors that influence the equity of Mersana Therapeutics?

Some factors that can affect the equity of Mersana Therapeutics include profits, dividend payments, capital increases, and acquisitions.

Why is the equity of Mersana Therapeutics so important for investors?

The equity of Mersana Therapeutics is important for investors as it is an indicator of the financial strength of the company and can be an indication of how well the company is able to fulfill its financial obligations.

What strategic measures can Mersana Therapeutics take to change the equity?

To change equity, Mersana Therapeutics can take various measures such as increasing profits, conducting capital increases, reducing expenses, and acquiring companies. It is important for the company to perform a thorough review of its financial situation to determine the best strategic actions to modify its equity.

How much dividend does Mersana Therapeutics pay?

Over the past 12 months, Mersana Therapeutics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Mersana Therapeutics is expected to pay a dividend of 0 USD.

What is the dividend yield of Mersana Therapeutics?

The current dividend yield of Mersana Therapeutics is .

When does Mersana Therapeutics pay dividends?

Mersana Therapeutics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Mersana Therapeutics?

Mersana Therapeutics paid dividends every year for the past 0 years.

What is the dividend of Mersana Therapeutics?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Mersana Therapeutics located?

Mersana Therapeutics is assigned to the 'Health' sector.

Wann musste ich die Aktien von Mersana Therapeutics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Mersana Therapeutics from 5/13/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 5/13/2024.

When did Mersana Therapeutics pay the last dividend?

The last dividend was paid out on 5/13/2024.

What was the dividend of Mersana Therapeutics in the year 2023?

In the year 2023, Mersana Therapeutics distributed 0 USD as dividends.

In which currency does Mersana Therapeutics pay out the dividend?

The dividends of Mersana Therapeutics are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

The Mersana Therapeutics stock can be added to a savings plan with the following providers: Trade Republic

Andere Kennzahlen von Mersana Therapeutics

Our stock analysis for Mersana Therapeutics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Mersana Therapeutics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.